经分数式红外激光消融的皮肤接种——激光参数与佐剂的优化
该研究用消融分数式红外激光(P.L.E.A.S.E. Professional)在小鼠皮肤造微孔递送乙肝表面抗原(HBsAg)等疫苗,优化激光能量密度与孔密度并测试多种佐剂。结果显示抗体滴度取决于孔深度,在8.4J/cm2达峰,与孔密度无关;明矾佐剂显著降低经皮免疫抗体滴度,LT-B与CpG改变免疫应答极化;ActHIB®与Menveo®经皮免疫可诱导与肌内注射相当的高抗体滴度。
要点
- 抗体滴度取决于孔深度,在能量密度8.4J/cm2时达峰,与孔密度无关。
- 明矾佐剂显著降低经皮免疫后的抗体滴度,为经激光微孔经皮接种的禁忌佐剂。
- 无明矾配方的市售疫苗经激光微孔经皮接种可诱导与肌内注射相当的高抗体滴度。
核心结论
- 明矾为最常用佐剂,但为经激光生成微孔经皮接种的禁忌佐剂。
- 优化激光参数的经皮免疫可诱导高抗体滴度,测试的佐剂未能显著提高该滴度。
- 不含明矾配方的市售疫苗无需重新配制即可通过激光微孔成功经皮接种。
研究设计与样本
- BALB/c小鼠经激光微孔以乙肝表面抗原(HBsAg)免疫。
- 所用佐剂为明矾、CRM197、单磷酰脂质A、大肠埃希菌不耐热肠毒素B亚单位(LT-B)与CpG ODN1826。
- 研究了不同能量密度(2.1至16.8J/cm2)与孔密度(5%–15%)的影响。
- 比较了HBsAg及市售结合疫苗ActHIB®与Menveo®经皮免疫与标准肌内注射的免疫原性。
- 抗原特异性抗体滴度用发光酶联免疫吸附试验评估。
主要发现
- 抗HBsAg抗体滴度取决于孔深度,在能量密度8.4J/cm2时达峰。
- 免疫原性与孔密度无关。
- 明矾佐剂显著降低经皮免疫后的抗体滴度,其他佐剂仅使总IgG滴度发生边缘变化。
- LT-B与CpG使IgG1/IgG2a比值下降,提示免疫应答极化改变。
- 经皮免疫HBsAg/LT-B诱导的抗体滴度与肌内注射HBsAg/明矾相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methods to deliver an antigen into the skin in a painless, defined, and reproducible manner are essential for transcutaneous immunization (TCI). Here, we employed an ablative fractional infrared laser (P.L.E.A.S.E. Professional) to introduce clinically relevant vaccines into the skin. To elicit the highest possible antibody titers with this system, we optimized different laser parameters, such as fluence and pore number per area, and tested various adjuvants. METHODS: BALB/c mice were immunized with Hepatitis B surface antigen (HBsAg) by laser-microporation. Adjuvants used were alum, CRM197, monophosphoryl lipid A, heat-labile enterotoxin subunit B of E. coli (LT-B), and CpG ODN1826. The influence of different fluences (2.1 to 16.8J/cm2) and pore densities (5-15%) was investigated. Furthermore, immunogenicity of HBsAg and the commercially available conjugate vaccines ActHIB® and Menveo® applied via TCI was compared to standard i.m. injection. Antigen-specific antibody titers were assessed by luminometric ELISA. RESULTS: Antibody titers against HBsAg were dependent on pore depth and peaked at a fluence of 8.4J/cm2. Immunogenicity was independent of pore density. Adjuvantation with alum significantly reduced antibody titers after TCI, whereas other adjuvants only induced marginal changes in total IgG titers. LT-B and CpG shifted the polarization of the immune response as indicated by decreased IgG1/IgG2a ratios. HBsAg/LT-B applied via TCI induced similar antibody titers compared to i.m. injection of HBsAg/alum. In contrast to i.m. injection, we observed a dose response from 5 to 20μg after TCI. Both, ActHIB® and Menveo® induced high antibody titers after TCI, which were comparable to i.m. injection. CONCLUSIONS: Alum, the most commonly used adjuvant, is contraindicated for transcutaneous vaccination via laser-generated micropores. TCI with optimized laser parameters induces high antibody titers, which cannot be significantly increased by the tested adjuvants. Commercially available vaccines formulated without alum have the potential for successful TCI via laser-generated micropores, without the need for reformulation.
引用
- Scheiblhofer S, Strobl A, Hoepflinger V, et al. Skin vaccination via fractional infrared laser ablation - Optimization of laser-parameters and adjuvantation. Vaccine. 2017. PMID: 28117172. doi:10.1016/j.vaccine.2016.11.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。